COMMUNIQUÉS West-GlobeNewswire

NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
12/02/2026
Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its [...]
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
12/02/2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness. 2026 guidance reflects continued growth in Travel Health (10% from own [...]
Ipsen réalise de solides résultats en 2025, grâce à une performance soutenue de toutes les aires thérapeutiques, et annonce ses objectifs 2026
12/02/2026
Croissance des ventes totales du Groupe en 2025 de 10,9% à taux de change constant 1 (8,1% en données publiées), tirée par la croissance des trois aires thérapeutiques avec une croissance de 4,1% 1 en Oncologie, 102,5% [...]
BioRestorative Announces Pricing of $5.0 Million Public Offering
12/02/2026
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell- [...]
Xilio Therapeutics Announces Pricing of Underwritten Offering
12/02/2026
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
11/02/2026
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results
11/02/2026
SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and [...]
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
11/02/2026
Launch of Inspire V system complete with strong revenue and profitability performance in the fourth quarter and FDA approval for 3.0T MRI compatibility Fourth quarter revenue growth of 12% and full year revenue growth [...]
Java Burn Drops Product Information Updated as Consumer Interest in Liquid Coffee Supplement Options for Weight Management Grows in 2026
11/02/2026
An informational overview examining liquid coffee supplement category context, publicly available Java Burn Drops product disclosures, and what consumers often consider when researching coffee-based weight management [...]
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
11/02/2026
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 [...]
Biogen Announces Board Chair Transition
11/02/2026
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced [...]
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
11/02/2026
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/02/2026
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
Regeneron Announces Investor Conference Presentations
11/02/2026
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on [...]
Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure
11/02/2026
Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that [...]
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
11/02/2026
Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon ® CNP under FDA Priority Review [...]
Etienna Bio, Inc. Announces Formation of Scientific Advisory Board with Renowned UMass Chan Leaders
11/02/2026
Silvia Corvera, MD, and Michael Czech, PhD, Join SAB to Advance Autologous Regenerative Cell Platform LEAWOOD, Kan., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a regenerative biotechnology company developing [...]
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
11/02/2026
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth [...]

Pages